Related Experiment Videos
Insights
Trimethoprim-sulfamethoxazole (TMP-SMZ) significantly reduced subsequent infections in children with cancer and bacterial sepsis. This antibiotic combination therapy proved beneficial for both neutropenic and non-neutropenic patients.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Pharmacology
Background:
- Children with cancer are susceptible to bacterial sepsis and recurrent infections.
- Neutropenia in cancer patients increases the risk of severe infectious complications.
- Antibiotic treatment for sepsis requires careful management to prevent re-infection.
Purpose of the Study:
- To evaluate the efficacy of trimethoprim-sulfamethoxazole (TMP-SMZ) in preventing subsequent infections in pediatric cancer patients post-sepsis.
- To compare infection rates in patients receiving TMP-SMZ versus those not receiving it after antibiotic treatment for sepsis.
Main Methods:
- Observational study of 100 children with cancer and bacterial sepsis.
- Patients were followed for one month after antibiotic treatment completion.
- Treatment groups included those maintained on TMP-SMZ and a control group without TMP-SMZ.
Main Results:
- TMP-SMZ significantly reduced infection episodes in neutropenic patients (36% vs. 88%).
- Similar significant reductions in infections were observed in non-neutropenic patients.
- Infections were twice as frequent in non-recipients among children in malignancy relapse.
- No deaths occurred in the TMP-SMZ group during the observation period.
Conclusions:
- TMP-SMZ administration post-bacterial sepsis effectively reduces infectious episodes in pediatric cancer patients.
- The benefits of TMP-SMZ were noted in both neutropenic and non-neutropenic patients, excluding non-neutropenic patients in remission.
- TMP-SMZ may be a valuable prophylactic agent in this high-risk population.
Abstract:
One hundred children with cancer and bacterial sepsis were observed for one month after completion of antibiotic treatment for subsequent episodes of infection. After satisfactory clinical and bacteriological responses were achieved and antibiotic therapy terminated, 38 of the patients were maintained on trimethoprim--sulfamethoxazole (TMP-SMZ) and 62 did not receive the drug combination. Of the 26 neutropenic patients not receiving TMP-SMZ 23 (88%) had episodes of infection, whereas 4 (36%) of the 11 given the drug had recurrent or re-infection episodes (P = less than 0.001). A difference of similar significance was observed in the non-neutropenic patients. Infections in children in relapse of their malignancy were twice as frequent in those not receiving the drug as in those who received it (P = less than 0.02, greater than 0.01). Of the 19 patients who died during the month of observation, none had received TMP--SMZ. This study shows that the administration of TMP--SMZ after bacterial sepsis reduces the number of infectious episodes in neutropenic and non-neutropenic patients, with the exception of the non-neutropenic patient in remission.